Alport Syndrome Pipeline Insight 2024, Featuring Eloxx Pharmaceuticals, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics and Reata Pharmaceuticals
April 11, 2024 11:04 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Alport Syndrome - Pipeline Insight, 2024" has been added to ResearchAndMarkets.com's offering.The "Alport Syndrome - Pipeline Insight, 2024," report...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Reata Pharmaceuticals, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important February 18 Deadline in Securities Class Action – RETA
January 25, 2022 16:56 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between...